RxDoctor Payments Data

Daniel Feldman, MD

Interventional Cardiology · Portland, ORNPI 1033351093

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $32,475 of the $36,197 with a category attached, or 89.7%. Abiomed accounts for 90.3% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $32,734, more than ten times the $100 reported in 2019.

$36,197in general payments, 2019–2025

Across 71 payments — averaging $509.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$33K
  • Abbott$2K
  • Medtronic$618
  • Edwards Lifesciences$520
  • Boston Scientific$285
  • Biosense Webster, Inc.$144
  • plus $342 from 8 others

What the payments were for

  • Consulting fees$32,47590%
  • Travel & lodging$1,2473%
  • Food & beverage$2,4757%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,197 in reported general payments places this provider in the 75th percentile of 68 interventional cardiology providers in Oregon.

See all interventional cardiology providers in Oregon

Medicare billing

Part B allowed, 2024
$119,237
Medicare patients
230
Services billed
791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$94,034
XareltoRivaroxaban17$20,770
EntrestoSacubitril/Valsartan12$13,472
Metoprolol Succinate105$1,381
ClopidogrelClopidogrel Bisulfate71$928
Atorvastatin Calcium99$885
Torsemide14$555
Carvedilol44$466
Metoprolol Tartrate55$399
Isosorbide Mononitrate ErIsosorbide Mononitrate32$364
Furosemide58$336
Losartan Potassium29$237
Rosuvastatin Calcium12$225
Amlodipine Besylate45$207
Lisinopril35$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$119$94,03485 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 68 interventional cardiology providers in Oregon.

Other interventional cardiology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →